Berlin-based neurotech startup Insellar has secured €400,000 in pre-seed funding to develop a patented brain-computer interface aimed at treating treatment-resistant depression.
The round was backed by IBB Ventures, alongside business angels and experts from neurosurgery, psychiatry, and neurotechnology. Founded in July 2025, the company is developing a system designed to modulate brain activity as a potential new approach for patients who do not respond to existing therapies.
Insellar said the funding will support further technology development, the buildout and validation of a functional prototype, preclinical proof-of-concept work, and preparations for clinical development in Europe and the US. The startup also sees potential for the platform in other mental health indications over time.
The round was backed by IBB Ventures, alongside business angels and experts from neurosurgery, psychiatry, and neurotechnology. Founded in July 2025, the company is developing a system designed to modulate brain activity as a potential new approach for patients who do not respond to existing therapies.
Insellar said the funding will support further technology development, the buildout and validation of a functional prototype, preclinical proof-of-concept work, and preparations for clinical development in Europe and the US. The startup also sees potential for the platform in other mental health indications over time.